REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule MEK 1/2 inhibitor. The platform analyzed cellular models of APC gene loss-the root cause of FAP-to identify compounds ...

Oral hormone therapy may benefit heart health in menopausal women. A new analysis of data from the Women's Health Initiative found that estrogen-based oral hormone therapy had a long-term beneficial ...

Sylvie Grégoire, Chair of Abivax Board of Directors, commented: “We are delighted to welcome Dominik to the Board at such a pivotal moment for Abivax. His extensive background in global medical ...

A proof-of-concept study will test VAS-101, a topical gel using the turmeric extract curcumin, in sickle cell disease (SCD) ...

Research from Harvard Forest identified a crucial relationship between precipitation patterns and soil types in New England.

Visit https://www.apbioinc.com/en/ for more information about AP Biosciences and its pipeline of next-generation cancer therapies.

Neuroscientists have developed a new treatment approach for a language disorder that combines traditional speech therapy with noninvasive electrical stimulation of the brain. Brain stimulation helped ...

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

Blood pressure is known to be a risk factor for developing dementia. A study, published in the journal 'Neurology' in January ...

Clinical trials improve care and access to novel treatments for advanced gastrointestinal cancers, says Dr. Michael Pishvaian ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Learn more about whether Alvotech or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...